Abstracts of the MASCC/ISOO 2017 Annual Meeting

Mette Marcussen(Aalborg University), Hans Erik Johnsen(Herlev Hospital), Mads Sønderkær(Aalborg University), Mogens Vyberg(Aalborg University Hospital), Julie Støve Bødker(Chr. Hansen (Denmark)), Maria Andersen(Norwegian University of Science and Technology), Martin Bøgsted(Chr. Hansen (Denmark)), Olav J. Bergmann(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Søren Nielsen(Aalborg University Hospital), Ilse Christiansen(Aalborg University Hospital)

Supportive Care in Cancer

April 22, 2017

10.1007/s00520-017-3704-x

Cited by 24

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder

|Journal of Medicinal Chemistry|2011|602

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362